WAP
ADAP

Wealthcare Advisory Partners’s Adaptimmune Therapeutics ADAP Stock Holding History

Wealthcare Advisory Partners’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,050
Closed -$8K – 333
2020
Q1 		$8K Buy
+3,050
New +$10.1K ﹤0.01% 964

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wealthcare Advisory Partners's ADAP Position: Q2 2020 in Review

Wealthcare Advisory Partners sold out of Adaptimmune Therapeutics (ADAP) in Q2 2020, closing a stake of 3,050 shares — an estimated $8K sold.

Wealthcare Advisory Partners first reported a position in ADAP in Q1 2020 and held it in 1 quarter. The position peaked at $8K in Q1 2020. 77 funds tracked by Wall St. Rank hold ADAP as of Q2 2020.

  • Wealthcare Advisory Partners reported no remaining Adaptimmune Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Wealthcare Advisory Partners sold 3,050 Adaptimmune Therapeutics shares in Q2 2020, an estimated $8K.
  • Wealthcare Advisory Partners first reported a position in Adaptimmune Therapeutics in Q1 2020 and held it in 1 quarter.
  • Wealthcare Advisory Partners's Adaptimmune Therapeutics position peaked at $8K in Q1 2020.
  • 77 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2020.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2020, filed 29 Jul 2020.